deltatrials
Completed PHASE3 NCT00674739

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts

Sponsor: Graceway Pharmaceuticals, LLC

Conditions Genital Warts
Interventions 3.75% imiquimod cream Imiquimod placebo cream
Updated 8 times since 2017 Last updated: May 19, 2011 Started: May 31, 2008 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This PHASE3 trial investigates Genital Warts and is currently completed. Graceway Pharmaceuticals, LLC leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Graceway Pharmaceuticals, LLC
Data source: Graceway Pharmaceuticals, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States, Atlanta, United States, Augusta, United States, Austin, United States, Boynton Beach, United States, Colorado Springs, United States, Dallas, United States, Denver, United States, Fountain Valley, United States, Fremont, United States and 18 more location s